0001209191-23-046102.txt : 20230816
0001209191-23-046102.hdr.sgml : 20230816
20230816181128
ACCESSION NUMBER: 0001209191-23-046102
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230814
FILED AS OF DATE: 20230816
DATE AS OF CHANGE: 20230816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galimi Francesco
CENTRAL INDEX KEY: 0001823996
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 231179351
MAIL ADDRESS:
STREET 1: 12930 VIA ESPERIA
CITY: DEL MAR
STATE: CA
ZIP: 92014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-14
0
0001720580
Adicet Bio, Inc.
ACET
0001823996
Galimi Francesco
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
0
1
0
0
SVP & Chief Medical Officer
0
Stock Option (Right to Buy)
5.97
2023-08-14
4
D
0
113652
0.00
D
2029-10-15
Common Stock
113652
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
113652
0.00
A
2029-10-15
Common Stock
113652
113652
D
Stock Option (Right to Buy)
16.11
2023-08-14
4
D
0
77269
0.00
D
2030-09-16
Common Stock
77269
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
77269
0.00
A
2030-09-16
Common Stock
77269
77269
D
Stock Option (Right to Buy)
13.27
2023-08-14
4
D
0
73964
0.00
D
2031-01-12
Common Stock
73964
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
73964
0.00
A
2031-01-12
Common Stock
73964
73964
D
Stock Option (Right to Buy)
16.82
2023-08-14
4
D
0
26625
0.00
D
2031-02-11
Common Stock
26625
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
26625
0.00
A
2031-02-11
Common Stock
26625
26625
D
Stock Option (Right to Buy)
15.52
2023-08-14
4
D
0
125000
0.00
D
2032-01-06
Common Stock
125000
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
125000
0.00
A
2032-01-06
Common Stock
125000
125000
D
Stock Option (Right to Buy)
9.05
2023-08-14
4
D
0
117200
0.00
D
2033-01-23
Common Stock
117200
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
117200
0.00
A
2033-01-23
Common Stock
117200
117200
D
On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
A total of 128,424 shares subject to an employee stock option were granted to the Reporting Person on September 15, 2020, with 25% of the shares subject to this option vested and exercisable on September 23, 2020, and the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 14,772 shares subject to this option.
The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 6,036 shares subject to this option.
A total of 28,400 shares subject to an employee stock option were granted on February 12, 2023, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 1,775 shares subject to this option.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
/s/ Nick Harvey, Attorney-in-Fact
2023-08-16